Next Article in Journal
Probiotics, the Immune Response and Acute Appendicitis: A Review
Next Article in Special Issue
Proceedings of the Online Conference “Vaccines and Vaccination during and Post COVID Pandemics” (7–9 December 2022)
Previous Article in Journal
Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom
Previous Article in Special Issue
DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond
 
 
Article
Peer-Review Record

Development and Optimal Immune Strategy of an Alum-Stabilized Pickering emulsion for Cancer Vaccines

Vaccines 2023, 11(7), 1169; https://doi.org/10.3390/vaccines11071169
by Sha Peng 1,2,3, Yumeng Yan 1,4, To Ngai 5, Jianjun Li 1,4,6, Kenji Ogino 2,3,* and Yufei Xia 1,4,6,*
Reviewer 1: Anonymous
Vaccines 2023, 11(7), 1169; https://doi.org/10.3390/vaccines11071169
Submission received: 22 May 2023 / Revised: 25 June 2023 / Accepted: 26 June 2023 / Published: 28 June 2023

Round 1

Reviewer 1 Report

The manuscript titled " Development and optimal immune strategy of alum-stabilized Pickering emulsion for cancer vaccines" is a good work wherein the authors have reported synthesis of an Alum-stabilized Pickering Emulsion (APE) that can load a high number of antigens which continue to release for extensive maturation and activations of antigen presenting cells (APCs). However I have detected certain issues which need to be  addressed extensively for improving the quality of the paper.

1. In the introduction section, the authors are not very clear about the need to carry out the research.

2. Many grammatical errors and English language issues mar the quality of the paper.

3. I could find many literature precedents with almost the same results. The authors should clearly mention all related previous published works  and highlight the improvements made in their work.

 Many grammatical errors and English language issues mar the quality of the paper. Extensive language and grammatical corrections need to be carried out.

Author Response

We deeply appreciate and treasure the reviewer’s comments and the constructive suggestions, which strongly inspired and encouraged us to work on the revised manuscript. In light of the comments, we have carefully collected, analyzed and summarized the relative literature and made some revisions, and the details have been put in the attachment, please check it.

Author Response File: Author Response.docx

Reviewer 2 Report

This paper describes experimental observations in relation to the efficay of an adjuvant for cancer vaccination. It extends previous significant work developed by the same authors regarding the fine tunning of the adjuvant.

The paper is well written and understandable. Methods are well described. Figures are well presented

The English text should be carefully revised and improved.

While results support the efficacy of the vaccination procedure, the Discussion of this paper is lacking  a comparison with other applied adjuvants and vaccination protocols, in such a way that the authors should highlight the advantages and limitations of their methodology.

Comments for author File: Comments.pdf

The English text should be carefully revised and improved.

Author Response

We deeply appreciate and treasure the reviewer’s comments and the constructive suggestions, which strongly inspired and encouraged us to work on the revised manuscript. In light of the comments, we have carefully collected, analyzed and summarized the relative literature and made some revisions, and the details have been put in the attachment, please check it. 

Author Response File: Author Response.docx

Reviewer 3 Report

The authors of the paper “Development and optimal immune strategy of alum-stabilized Pickering emulsion for cancer vaccines” give us an overview of a potential usage in cancer vaccines of a stabilized alum-squalene adjuvant.

 

The article need English editing, but major and minor issues are found in this article:

 

Major issues:

 

1-    Alum-stabilized Pickering emulsion: There is no evidence of a chemical/biological stability of this adjuvant.

2-    Method part: The method part should be re-written. The vaccine schedule is missing. and we do not understand the downstream analysis.

3-    Results and Discussions: There is no discussion in the article. References are missing in this crucial part of the article.

4-    Supplemental figures are also missing in the submission, we cannot review them.

5-    In this study, we miss the important comparison with Alum-OVA only (not as APE). This is a crucial result to see the real biological impact of this new formulation.

6-    Figure 5d and Figure 8c: The Vaccination and the Vaccination+anti-PD1 protocol are finally not protective, even with 3 and 4 immunization. We do not see any greater potential for potent anti-tumor effect.

 

Minor issues:

 

1-    Line 102: 2.3 Cell culture, this is not the real title as you are talking about mice.

2-    Line 157, why you resuspend cells in whole blood and tissue diluent?

3-    2.9 and 2.10, did you evaluate the weight loss of your mice during the protocol? This is important to check the illness of these mice.

4-    Table 1, why you have this enormous size difference between Alum and APE? They both have similar loading efficiencies.

5-    Line 214, why you talk about COVID19? No reference.

6-    Figure 4: Pictures are very small; we cannot see if there are immune cell infiltration differences.

The article need moderate English editing. 

Author Response

We deeply appreciate and treasure the reviewer’s comments and the constructive suggestions, which strongly inspired and encouraged us to work on the revised manuscript. In light of the comments, we have carefully collected, analyzed and summarized the relative literature and made some revisions, and the details have been put in the attachment. Please check it.

Author Response File: Author Response.docx

Round 2

Reviewer 2 Report

The authors have paid attention to former comments, and have greatly modified and improved the Introduction and Discussion of the paper, providing a convincing answer to those. Accordingly, References  have also been revised.

Maybe the Section 3 should better read  just  “Results”  instead of “Results and  Discussions”.

Section 4 might be “Discussion”  or  “Discussion and conclusions”.

The English text contains some mistakes that should be corrected.

 

Comments for author File: Comments.pdf

The English text contains some mistakes that should be corrected.

Author Response

We are encouraged by the reviewer’s comment. We also want to express our gratitude for the referee’s dedication and support for our work, which aided in preparing the revised manuscript. We apologize for the mistakes in the writings of the previous version. In light of the comment, The Section 3 and the Section 4 have been revised to “Results” and“Discussion” respectively. Then, we have carefully checked and improved the use of English, which have been highlighted in yellow in the revised manuscript. We sincerely appreciate reviewer’s work, and hope that it would meet with the expectation.

Author Response File: Author Response.docx

Reviewer 3 Report

Thank you for editing the manuscripts regarding my comments.

Better English than the previous version.

Author Response

We are encouraged by the reviewer’s comment. We also want to express our gratitude for the referee’s dedication and support for our work, which aided in preparing the revised manuscript. We apologize for the mistakes in the writings of the previous version. In light of the comment, we have carefully checked and improved the use of English, which have been highlighted in yellow in the revised manuscript. We sincerely appreciate reviewer’s work, and hope that it would meet with the expectation.

Author Response File: Author Response.docx

Back to TopTop